Compare ConocoPhillips (COP) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ConocoPhillips vs Cassava Sciences Inc — how do they compare? ConocoPhillips trades at $111.54 (market cap $136.29B), while Cassava Sciences Inc trades at $1.09 (market cap $52.66M). The key difference: ConocoPhillips is far larger — about 2588.1× Cassava Sciences Inc's market cap, and ConocoPhillips pays a 3% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| COP | FLNA | |
|---|---|---|
Market Cap | $136.29B | $52.66M |
Sector | Energy | Health |
52-Week High | $133.80 | $4.64 |
52-Week Low | $85.66 | $1.09 |
Enterprise Value | $153.25B | -$33.92M |
Dividend Yield | 3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $112.85, up 3.49% today, with a bullish technical outlook supported by moving averages and strong analyst consensus. The company reported mixed Q1 2026 earnings, beating EPS estimates but showing declining revenue and net income margins since 2022. Recent news highlights oil price volatility and geopolitical risks influencing energy stocks.
COP offers value with a P/E of 19.13 and bullish analyst targets averaging $137.14, but faces headwinds from falling profitability and oil market instability. Investment appeal hinges on execution amid volatile commodity prices and competitive pressures.
FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.
Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
